Get startedLog in
    Picture of Vicore Pharma Holding AB logo

    VICO — Vicore Pharma Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Vicore Pharma: Update On Progress In Clinical Lead Program VP01 (C21)

    Picture of Vicore Pharma Holding AB logoVicore Pharma Holding AB
    01/10/2019 07:17
    Oct 1 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * UPDATE ON PROGRESS IN CLINICAL LEAD PROGRAM VP01 (C21)
    * A PHASE II CTA (CLINICAL TRIAL APPLICATION) HAS BEEN FILED
WITH
MHRA, REGULATORY BODY IN UK, FOR STUDYING EFFECT OF A SINGLE
DOSE OF C21 ON COLD INDUCED VASOCONSTRICTION IN SUBJECTS WITH
SYSTEMIC SCLEROSIS (SSC)

Source text for Eikon:  ID:nWkr5TWWfg 
Further company coverage:  VICOR.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Vicore Pharma Holding AB

    See all news